What the public record says
On 13 April 2026, the TGA published a safety advisory on unapproved peptide products. It names BPC-157, GHK-Cu, TB-500, retatrutide, and CJC-1295 as examples and warns that unclear labels, code-only products, research-use disclaimers, and public advertising can still create regulatory and public-health risk.
What buyers should check
- The TGA says peptide products are regulated as therapeutic goods in Australia.
- The advisory names BPC-157, GHK-Cu, TB-500, retatrutide, and CJC-1295 as examples of unapproved peptide products.
- The TGA warns that unapproved products have not been assessed for safety, quality, or effectiveness.
- Products identified only by codes or unclear labels may not be assessed for release under the Personal Importation Scheme.
- A research-use-only disclaimer does not by itself change regulatory status, permit importation, or remove advertising and supply obligations.
Source links
Use this regulatory brief to ask better supplier questions. Do not convert a market-level warning into a vendor-specific claim unless the vendor page has a source attached.
Open vendor scorecards